The quinobenzoxazines: Relationship between DNA binding and biological activity

Anti-Cancer Drug Design

Volumn 14, Issue 5, 1999, Pages 443-450

  Kwok, Yan ^c   Sun, Daekyu ^a   Clement, Jacob J ^b   Hurley, Laurence H ^c  

^a CTRC Institute for Drug Development   (United States)

^b Scriptgen Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Antitumor activity; Quinobenzoxazine; Topoisomerase II

Indexed keywords

1 (3 AMINO 1 PYRROLIDINYL) 2 FLUORO 4 OXO 4H QUINO[8,1A,1 B,C][1,4]BENZOXAZINE 5 CARBOXYLIC ACID; BENZOXAZINE DERIVATIVE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); NORFLOXACIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA PROTEIN COMPLEX; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DNA BINDING; HUMAN; KINETOPLAST; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA; DNA FOOTPRINTING; HUMANS; MICE; MOLECULAR SEQUENCE DATA; OXAZINES; TUMOR CELLS, CULTURED;

MURINAE;

EID: 0033496946     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Capranico G., Zunino F. (1990) Structural requirements for DNA topoisomerase II inhibition by anthracyclines. In Molecular Basis of Specificity in Nucleic Acid-Drug Interactions. Pullman B., Jortner J. (eds), p. 167. Kluwer Academic Publishers: Dordrecht.
2. Capranico G., Zunino F., Kohn K.W., Pommier Y. (1990) Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry, 29, 562.
3. Chen A.Y., Liu L.F. (1994) DNA topoisomerases: essential enzymes and lethal targets. Annual Review of Pharmacology and Toxicology, 34, 191.
4. Chen M., Beck W.T. (1993) Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Research, 53, 5946.
5. Chu D.T.W., Hallas R., Clement J.J., Alder J., McDonald E., Plattner J.J. (1992) Synthesis and antitumor activities of quinolone antineoplastic agents. Drugs under Experimental and Clinical Research, 18, 275.
6. Corbett A.H., Osheroff N. (1993) When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chemical Research in Toxicology, 6, 585.
7. De Isabella P., Capranico G., Palumbo M., Sissi C., Krapcho A.P., Zunino F. (1993) Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. Molecular Pharmacology, 43, 715.
8. Dobbs S.T., Cullis P.M., Maxwell A. (1992) The cleavage of DNA at phosphorothioate internucleotidic linkages by DNA gyrase. Nucleic Acids Research, 20, 3567.
9. 2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex. Journal of Medicinal Chemistry, 38, 408.
10. Jensen P.B., Sorensen B.S., Sehested M., Demant E.J., Kjeldsen E., Friche E., Hansen H.H. (1993) Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochemical Pharmacology, 45, 2025.
11. Kwok Y., Zeng Q., Hurley L.H. (1999) Structural insight into a quinolone-topoisomerase II-DNA complex. Journal of Biological Chemistry, 274, 17226
12. Liu L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry, 58, 351.
13. Marini J.C., Miller K.G., Englund P.T. (1980) Decatenation of kinetoplast DNA by topoisomerases. Journal of Biological Chemistry, 255, 4976.
14. Osheroff N., Corbett A.H., Robinson M.J. (1994) Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Advances in Pharmacology, 29B, 105
15. Permana PA, Snapka R.M., Shen L.L., Chu D.T., Clement J.J., Plattner J.J. (1994) Quinobenzoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry, 33, 11333.
16. Pommier Y. (1997) DNA topoisomerase II inhibitors. In Cancer Therapeutics: Experimental and Clinical Agents. Teicher B.A. (ed.), p. 153. Humana Press: Totowa, NJ.
17. Sahai B.M., Kaplan J.G. (1986) A quantitative decatenation assay for type II topoisomerases. Analytical Biochemistry, 156, 364.
18. Sehested M., Jensen P.B. (1996) Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochemical Pharmacology, 51, 879.
19. Shen L.L., Baranowski J., Pernet A.G. (1989) Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry, 28, 3879.
20. Wang J.C. (1996) DNA topoisomerases. Annual Review of Biochemistry, 65, 635.
21. Watt P.M., Hickson I.D. (1994) Structure and function of type II DNA topoisomerases. Biochemical Journal, 303, 681.